Bevacizumab for neovascular ocular diseases

Annals of Pharmacotherapy

Volumn 41, Issue 4, 2007, Pages 614-625

  Lynch, Shalini S ^a   Cheng, Christine M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Intravitreal bevacizumab; Macular; Retinopathy

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB;

ANTERIOR CHAMBER INFLAMMATION; BLURRED VISION; BRAIN HEMORRHAGE; CORNEA ABRASION; CORNEA DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DIZZINESS; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE DISCOMFORT; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; FOLLOW UP; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE ABNORMALITY; MYOPIA; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); OPTIMAL DRUG DOSE; PATHOLOGICAL MYOPIA; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; REVIEW; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; SUBCONJUNCTIVAL HEMORRHAGE; TINNITUS; UVEITIS; VISUAL ACUITY; VITREOUS BODY; VITREOUS BODY DETACHMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DIABETIC RETINOPATHY; HUMANS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247182509     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H316     Document Type: Review

References (69)

1. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-85.
2. Age-related macular degeneration: what you should know. NIH publication no. 03-2294. Washington, DC: United States Department of Health and Human Services, National Institutes of Health, National Eye Institute, September 2003.
3. VEGF inhibitors and "wet" macular degeneration. American Macular Degeneration Foundation. www.macular.org/news/aarpvegf.html (accessed 2006 Apr 21).
4. Ng EWM, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-68.
5. Package insert. Avastin (bevacizumab). San Francisco, CA: Genentech Inc., September 2006.
6. Package insert. Lucentis (ranibizumab injection). San Francisco: Genentech, June 2006.
7. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Natl Rev Drug Discov 2004;3:391-400.
8. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-81.
9. Treatments for macular degeneration. AMD Alliance International. www.amdalliance.org/amd-info/personal/treatments/treatments.asp (accessed 2006 Mar 11).
10. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005;112:1035-47.
11. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:2002.e1-2002.e12.
12. Yoganathan P, Deramo VA, Lai JC, Tibrewala RJ, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 2006:26:994-8.
13. Aisenbrey S, Ziemssen F, Völker M, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol 2007. Epub 21 Dec 2006. DOI 10.1007/s00417-006-0471-7
14. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and ocular choroidal neovascularization secondary to age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol 2007;245:68-73. DOI 10.1007/s00417-006-0466-4
15. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina 2006;26:1006-13.
16. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
17. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevazicumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
18. Spaide RF, Laud K, Fine JFF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.
19. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
20. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short term study. Retina 2006;26:279-84.
21. Bashshur AF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin B. Intravitreal bevazicumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
22. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155-7.
23. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, Hernandez-Rojas M, Auiroz-Mercado H, Morales-Canton V. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefe's Arch Clin Exp Ophthalmol 2006 Sep 28. DOI 10.1007/s00417-006-0411-6
24. Aggio FB, Farah ME, Silva QC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefe's Arch Clin Exp Ophthalmol 2007;245:68-73. DOI 10.1007/s00417-006-0412-5
25. Dhalla M, Shah GK, Blinder KJ, Ryan EH, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-93.
26. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 2007;91:161-5. Epub 30 Aug 2006. DOI 10.1136/bjo.2006.099887
27. Hughes MS, Sang DN. Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2006;37: 446-54.
28. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-1695.e15.
29. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra G. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-6.
30. Ziemssen F, Deuter CM, Stuebiger N, Zierhut M. Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefe's Arch Clin Exp Ophthalmol. Epub 12 Jan 2007. DOI 10.1007/s00417-006-0512-2
31. Package insert. Macugen (pegaptanib sodium injection). New York: Eyetech Pharmaceuticals and Pfizer, March 2006.
32. Spaide RF, Klancnik J, Sorenson J, et al. Intravitreal bevacizumab for choroidal neovascularization secondary to age-related macular degeneration (abstract). Program 2962. Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting, Fort Lauderdale, FL, April 30-May 4, 2006.
33. Brooks HL Jr, Ashmore ED, Barker DL. Safety and efficacy of intravitreal Avastin for neovascular age-related macular degeneration (poster B627). Program 5212. Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting, Fort Lauderdale, FL, April 30-May 4,2006.
34. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;263:270-4.
35. Eichenbaum DA, Yates DA, Yamamoto I, et al. Intraocular bevacizumab (Avastin) for the treatment of choroidal neovascularization and retinal vasculopathies (abstract). Program 5253, poster B668. Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting, Fort Lauderdale, FL, April 30-May 4, 2006.
36. Wu L, Martinez-Castellanos M, Quiroz-Mercado H, et al. Safety of an intravitreal injection of bevacizumab (Avastin): results of a multicenter trial. Program PA018. Presented at: 2006 American Academy of Ophthalmology/Asia Pacific Academy of Ophthalmology Joint Meeting, Las Vegas, NV, November 12, 2006.
37. Eliwa TF, Hassan TS, Capone A, Drenser KA. Avastin rescue of failed treatment for wet AMD and other retinal vascular disease (poster B628). Program 5213. Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting, Fort Lauderdale, FL, April 30-May 4, 2006.
38. Thomas EL, Boyer DS, Novack RL. Chu TG, Gallemore RP, Rahhal FM. Ubiquity of vascular endothelial growth factor in retinal disease based on positive clinical responses to intravitreous bevacizumab (poster B580). Program 5650. Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting, Fort Lauderdale, FL, April 30-May 4, 2006.
39. Lalin SC, Dominguez J, Gentile RD, Muldoon TO, Rosen RB. Short-term outcomes in intravitreal bevacizumab (Avastin) for retinal or choroidal vascular disease at the New York Eye and Ear Infirmary (poster PO294). Presented at: 2006 American Academy of Ophthalmology/Asia Pacific Academy of Ophthalmology Joint Meeting, Las Vegas, NV, November 12, 2006.
40. Pelayes DE, Roca JA, Cortez RH, et al. Safety and tolerance of intraocular bevacizumab: a multicenter clinical trial (poster PO670). Presented at: 2006 American Academy of Ophthalmology/Asia Pacific Academy of Ophthalmology Joint Meeting, Las Vegas, NV, November 13, 2006.
41. Avery RL, Pieramici D, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab in the treatment of neovascular AMD (poster PO712). Presented at: 2006 American Academy of Ophthalmology/Asia Pacific Academy of Ophthalmology Joint Meeting, Las Vegas, NV, November 13, 2006.
42. Esfahani MR, Ahmadieh H, Faghihi H, et al. Intravitreal bevacizumab vs. bevacizumab combined with triamcinolone for neovascular AMD: six week efficacy results of a clinical trial (poster PO741). Presented at: 2006 American Academy of Ophthalmology/Asia Pacific Academy of Ophthalmology Joint Meeting, Las Vegas, NV, November 13, 2006.
43. Ahmadieh J, Ramezani A, Bijanzadeh B, et al. Bevacizumab vs. combined bevacizumab and triamcinolone for refractory diabetic macular edema: six week results of a clinical trial. Program PA014. Presented at: 2006 American Academy of Ophthalmology/Asia Pacific Academy of Ophthalmology Joint Meeting, Las Vegas, NV, November 12, 2006.
44. Pieramici DJ, Avery RL, Castellarin AA, Nasir MA, Rabena M. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina 2006;26:841-2.
45. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LAS Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-78. DOI 10;1167/iovs/06-0433
46. Kernt M, Neubauer AS, Kampik A. Intravitreal bevacizumab (Avastin) is safe in terms of intraocular and blood pressure. Acta Ophthalmologica Scandinavica 2007;85:1:119-20. DOI 10.1111/j.1600-0420.2006.00819.x
47. Chan CK, Gross JG, Meyer CH, et al. Retinal pigment epithelial tears following intraocular bevacizumab (Avastin) injection for neovascular AMD (poster PO703). Presented at: 2006 American Academy of Ophthalmology/Asia Pacific Academy of Ophthalmology Joint Meeting, Las Vegas, NV, November 13, 2006.
48. Spandau UHM, Jonas JB. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol 2006;142:1068-70.
49. Meyer CH, Mennel S, Schmidt JC, Kroll P. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularization secondary to age-related macular degeneration. Br J Ophthalmol 2006;90:1207-8. DOI 10.1136/bjo.2006.093732
50. Shah CP, Hsu J, Garg SJ, Fischer DH, Kaiser R. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol 2006;142:1070-2.
51. Gelisken F, Ziemssen F, Voelker M, Bartz-Schmidt KU. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Acta Ophtlmologica Scand 2006;84:833-4. DOI: 10.1111/j.1600-0420.2006.00765.x
52. Nicolo M, Ghiglione D, Calabria G. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur J Ophthalmol 2006;16:770-3.
53. Gibran SK, Sachdev A, Stappler T, Newsome R, Wong D, Hiscott P. Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab therapy (Avastin). Br J Ophthalmol 2007 Jan 4 [Epub ahead of print]. DOI:10.1136/bjo.2006.108795
54. Meyer CH, Mennel S, Hörle S, Schmidt JC. Visual hallucinations after intravitreal injection of bevacizumab in vascular age-related macular degeneration. Am J Ophthalmol 2007;143:169-70.
55. Fung AE, Rosenfeld PJ, Reichel EZ. The intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9. Epub 19 Jul 2006. DOI 10.1136/bjo.2006.099598
56. Ladewig MS, Ziemssen F, Jaissle G, et al. [Intravitreal bevacizumab for neovascular age-related macular degeneration] German. Ophthalmologe 2006;103:463-70. Epub 6 May 2006. DOI 10.1007/s00347-006-1352-5.
57. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreal injections. Retina 2004;24(5 suppl):S3-19.
58. Statement on Avastin. Position statement released by AMD Alliance International, www.amdalliance.org/information/treatments/treatments.php (accessed 2006 Sept 20).
59. Chakravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006;90:1188-96. DOI 10.1136/bjo.2005.082255
60. Risk management recommendations for off-label, intravitreal use of Avastin. American Academy of Ophthalmic Executives. www.omic.com/resources/ risk_man/forms.cfm. (accessed 2006 Sept 20).
61. ASHP technical assistance bulletin on pharmacy-prepared ophthalmic products. Am J Hosp Pharm 1993;50:1462-3.
62. Trissel L. An update on USP chapter 797: the new national standard for sterile preparation. www.ashpadvantage.com/website_images/pdf/hospira797.pdf (accessed 2006 Mar 6).
63. Bakri SJ, Snyder MR, Pulido JS, McCannel CA, Weiss WT, Singh RJ. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006;26:519-22.
64. Guerrero-Naranjo J, Bueno-Garcia R, Quiroz-Mercado H, et al. Security and side effects of intravitreal Avastin using two methods of storage (poster B447). Program 4501. Presented at: Association for Research in Vision and Ophthalmology 2006 Annual Meeting, Fort Lauderdale, FL, April 30-May 4, 2006.
65. Avastin (bevacizumab) 25 mg/mL (4 mL). Thomson Health Care Redbook Update 2006; 25:21.
66. Macugen (pegaptanib octasodium) 0.3 mg/0.09 mL (0.09 mL). Thomson Health Care Redbook Update 2005;24:42.
67. Witkowski W, Troise DJ. Genentech shares rise on FDA approval of Lucentis age-related blindness treatment. http://biz.yahoo.com/ap/060630/ genentech_novartis.html (accessed 2006 Aug 6).
68. www.clinicaltrials.gov (accessed 2006 Sept 20).
69. National Institutes of Health stimulates the development and testing of new therapies for advanced age-related macular degeneration (AMD). National Eye Institute Statement. http://www.nei.nih.gov/news/statements/amd_therapy.asp (accessed 2006 December 13).